EN
DE 
NL 
FR 
ES 
IT 
CS 
PL CONDITION
Nausea and appetite loss, especially from chemotherapy and HIV/AIDS, are among the most established medical uses of cannabinoids, and synthetic THC medicines have been FDA-approved for decades.
Repeated vomiting after long-term cannabis use? See cannabinoid hyperemesis syndrome: how long to recover.
What the research says
The National Academies 2017 report found conclusive or substantial evidence that oral cannabinoids are effective for chemotherapy-induced nausea and vomiting. This is one of the clearest evidence bases in the field.
Approved medicines
Dronabinol (Marinol), a synthetic THC, is FDA-approved for chemotherapy-induced nausea and vomiting and for appetite loss and wasting in HIV/AIDS. Nabilone (Cesamet), a synthetic THC analogue, is approved for chemotherapy nausea. These are prescription products with defined dosing.
Appetite stimulation
THC is well known to stimulate appetite (the “munchies”), which is therapeutically useful in wasting conditions. CBD does not share this effect and can slightly blunt it.
At a glance
What to be careful about
These are prescription indications managed by clinicians. Self-treating serious illness with cannabis instead of proven care is dangerous. THC dosing must be careful in unwell or older patients.
Continue exploring
Dorsal Vagal Complex CB1 Signaling, Clinical CINV Trials, and Hyperemesis Risk
Preclinical and clinical neuropharmacology demonstrates that emesis is coordinated by the dorsal vagal complex in the brainstem (comprising the area postrema, nucleus tractus solitarius, and dorsal motor nucleus of the vagus) together with vagal 5-HT3 afferents in the gastrointestinal tract; activation of presynaptic CB1 receptors by delta-9-THC and mixed CB1/5-HT1A signaling by cannabidiol (CBD) suppresses retrograde neurotransmitter release along this emetic reflex arc (Parker et al., 2011, PubMed PMID 21175589). In clinical oncology, the National Academies concluded there is conclusive evidence that oral cannabinoids are effective antiemetics for chemotherapy-induced nausea and vomiting (CINV) (NASEM, 2017, PubMed PMID 28182367; Smith et al., 2015, Cochrane Review, PubMed PMID 26561360). The multicenter, double-blind, placebo-controlled Grimison Phase II/III crossover trial (N = 81) further showed that adding an oral 1:1 THC:CBD capsule to standard guideline-consistent antiemetics (5-HT3 antagonists, NK1 antagonists, and dexamethasone) increased complete response (no vomiting and no rescue medication) from 14% to 25% despite higher rates of transient sedation and dizziness (Grimison et al., 2020, Annals of Oncology, PubMed PMID 32707248).
Frequently Asked Questions
Which cannabinoid medicines are approved for chemotherapy-induced nausea and vomiting?
Synthetic oral delta-9-THC (dronabinol) and the synthetic THC analogue nabilone are FDA-approved for chemotherapy-induced nausea and vomiting (CINV) that has not responded adequately to conventional antiemetics, and dronabinol is also approved for HIV-associated anorexia.
Why are cannabinoids used as add-on or rescue therapy rather than replacing 5-HT3 and NK1 antagonists?
Modern antiemetic regimens combining a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and dexamethasone remain the first-line standard of care; clinical trials show cannabinoids work best as an adjunct for refractory or breakthrough nausea.
What is cannabinoid hyperemesis syndrome (CHS)?
Chronic, high-dose daily THC exposure can paradoxically downregulate CB1 receptors and disrupt TRPV1 gut signaling, causing cyclic severe vomiting and abdominal pain that typically resolves only after complete cessation of cannabis use.
English